Endosomal signalling via exosome surface TGF beta-1 by Shelke, Ganesh Vilas et al.
Full Terms & Conditions of access and use can be found at
https://www.tandfonline.com/action/journalInformation?journalCode=zjev20
Journal of Extracellular Vesicles
ISSN: (Print) 2001-3078 (Online) Journal homepage: https://www.tandfonline.com/loi/zjev20
Endosomal signalling via exosome surface TGFβ-1
Ganesh Vilas Shelke, Yanan Yin, Su Chul Jang, Cecilia Lässer, Stefan
Wennmalm, Hans Jürgen Hoffmann, Li Li, Yong Song Gho, Jonas Andreas
Nilsson & Jan Lötvall
To cite this article: Ganesh Vilas Shelke, Yanan Yin, Su Chul Jang, Cecilia Lässer, Stefan
Wennmalm, Hans Jürgen Hoffmann, Li Li, Yong Song Gho, Jonas Andreas Nilsson & Jan Lötvall
(2019) Endosomal signalling via exosome surface TGFβ-1, Journal of Extracellular Vesicles, 8:1,
1650458, DOI: 10.1080/20013078.2019.1650458
To link to this article:  https://doi.org/10.1080/20013078.2019.1650458
© 2019 The Author(s). Published by Informa
UK Limited, trading as Taylor & Francis
Group on behalf of The International Society
for Extracellular Vesicles.
View supplementary material 
Published online: 20 Sep 2019. Submit your article to this journal 
Article views: 2720 View related articles 
View Crossmark data Citing articles: 8 View citing articles 
Endosomal signalling via exosome surface TGFβ-1
Ganesh Vilas Shelke a,b*†, Yanan Yin a,c*, Su Chul Jang a, Cecilia Lässer a, Stefan Wennmalmd,
Hans Jürgen Hoffmanne,f, Li Lig, Yong Song Ghoh, Jonas Andreas Nilsson b and Jan Lötvall a
aKrefting Research Centre, Institute of Medicine, the Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; bDepartment of
Surgery, Institute of Clinical Sciences, the Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; cDepartment of
Biochemistry and Molecular Cell Biology, Shanghai Jiao Tong University, School of Medicine, Shanghai, China; dRoyal Institute of
Technology-KTH, Department of Applied Physics, Experimental Biomolecular Physics Group, SciLife Laboratory, Solna, Sweden; eDepartment
of Clinical Medicine, Aarhus University, Aarhus, Denmark; fDepartment of respiratory and Allergy, Aarhus University Hospital, Aarhus,
Denmark; gDepartment of Laboratory Medicine, Shanghai First People’s Hospital, Shanghai JiaoTong University, Shanghai, China;
hDepartment of Life Sciences, Pohang University of Science and Technology, Pohang, Republic of Korea
ABSTRACT
Extracellular vesicles such as exosomes convey biological messages between cells, either by surface-
to-surface interaction or by shuttling of bioactive molecules to a recipient cell’s cytoplasm. Here we
show that exosomes released by mast cells harbour both active and latent transforming growth
factor β-1 (TGFβ-1) on their surfaces. The latent form of TGFβ-1 is associated with the exosomes via
heparinase-II and pH-sensitive elements. These vesicles traffic to the endocytic compartment of
recipient human mesenchymal stem cells (MSCs) within 60 min of exposure. Further, the exosomes-
associated TGFβ-1 is retained within the endosomal compartments at the time of signalling, which
results in prolonged cellular signalling compared to free-TGFβ-1. These exosomes induce a migratory
phenotype in primary MSCs involving SMAD-dependent pathways. Our results show that mast cell-
derived exosomes are decorated with latent TGFβ-1 and are retained in recipient MSC endosomes,
influencing recipient cell migratory phenotype. We conclude that exosomes can convey signalling
within endosomes by delivering bioactive surface ligands to this intracellular compartment.
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Introduction
Cell-to-cell communication can occur via secreted
soluble mediators such as cytokines, bioactive proteins
and nucleotides [1–4]. After their release from the cell,
they act in an autocrine or paracrine manner to mod-
ulate cellular function. To achieve longer half-life,
secreted mediators can either exist in an inactive con-
formation by binding to pro-protein or interact with
extracellular matrix proteins, which requires activation
before a biological signal can be conveyed [5–7].
Activation can happen either by matrix degradation
or by proteolytic cleavage of matrix or pro-protein to
release bioactive molecules like transforming growth
factor beta-1 (TGFβ-1) [5,8].
In circulation, TGFβ-1 exists in an active and inactive
form in a ~ 1:65 ratio [9]. Inactive TGFβ-1 exists as
a dimer of pro-proteins consisting of latent binding
protein (LAP) and active-TGFβ-1 subunit. The role of
active-TGFβ-1 in activating the SMAD/non-SMAD sig-
nalling pathway has been extensively studied [10–12].
However, the exact mechanisms of inactive-TGFβ-1
activation are not well studied.
Previous studies have reported the association of TGFβ-1
with secretory structures called extracellular vesicles (EVs)
[13,14]. EVs, including exosomes andmicrovesicles, are nano-
to-micrometre sized, lipid bilayer-enclosed membrane struc-
tures that carry an array of bioactive molecules, including
proteins, nucleic acids, and lipids. In this study the term
“exosomes” is used for EVs, as the isolation procedures we
use are known to enrich for small EV. Extensive proteomics of
exosomes has highlighted the presence of TGFβ-1 in those
preparations [15–18]. Therefore, it would be important to
determine how the TGFβ-1 is associated with the exosomes,
including its topology. TGFβ-1 secreted from immune cells
regulates many processes, including migration and immuno-
modulation of recipient cells such as human mesenchymal
stem cells (MSCs). MSCs can regulate immune responses,
which has made them attractive therapeutic candidates in
several inflammatory diseases [19–24].
We hypothesized that highly bioactive surface mole-
cules on exosomes can convey rapid signalling in
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recipient cells. To investigate this, we first performed
membrane proteomics of exosomes released by mast
cells, and specifically looked for the presence of TGFβ-1.
We then confirmed the association of the form of TGFβ-1
to the exosome membranes and its coexistence with
characteristic exosome-associated proteins at single-
vesicle resolution. Lastly, the mechanism by which
TGFβ-1 is associated with the membrane was deter-
mined. Exosomes can rapidly traffic to the endosomal
compartment; thus, we also tested whether TGFβ-1 can
induce recipient cell signalling in the intercellular mem-
brane compartment.
Methods
Cell culture
Human bone marrow-derived mesenchymal stem cells
(MSCs) were obtained at passage 1 from the MSC distri-
bution at the Institute of Regenerative Medicine at Scott
and White, USA. The MSCs were cultured in Minimum
Essential Medium α-GlutaMAX™ Supplement (Life
Technologies, Thermo Fisher Scientific, Waltham, MA,
USA) supplemented with 15% fetal bovine serum (FBS;
Sigma Aldrich, St. Louis, MO, USA). The culture media
was changed to EV-depleted FBS-containing medium 24
h prior to experiments. The MSCs were used within 3–4
passages in all experiments, with a seeding density of 3000
cells/cm2. The human mast cells, HMC-1 (J, Butterfield,
Mayo Clinic, Rochester, MN, USA), were grown in
Iscove’s modified Dulbecco’s medium (IMDM, HyClone
Laboratories, Logan, UT, USA) supplemented with 10%
EV-depleted FBS, 2 mM L-glutamine (HyClone
Laboratories), and 1.2 mM α-thioglycerol (Sigma
Aldrich). HEK293T cells (ATCC, Manassas, VA, USA)
were grown in RPMI-1640 medium (HyClone
Laboratories) supplemented with 10% FBS. All cultures
were supplemented with 100 units/ml penicillin and 100
µg/ml streptomycin (HyClone Laboratories). Here, the
supplement FBS was depleted of EVs by ultracentrifuga-
tion for 18 h at 120,000 × g (Type 45 Ti rotor, Beckman
Coulter) as described earlier [57]. All cells were cultured at
37°C in a 5% CO2 humidified atmosphere. For the pur-
ification and culture of progenitor mast cells, we used
PBMC from healthy human donors. Briefly, mononuclear
cells were purified from PBMC, and the CD133+ cells were
isolated by MACS (Miltenyi Biotech, Germany). CD133+
cells were cultured in a serum-free medium (StemSpan,
StemCell technology, Vancouver Canada) supplemented
with SCF and IL-6. IL-3 was added for the first 2 weeks,
and IL-4 for the last 2 weeks. Cells were then maintained
for 6–7 weeks before the conditioned medium was har-
vested for exosomes isolation [58].
Isolation of exosomes
Using ultracentrifugation pelleting
Exosomes were isolated from conditioned cell medium
by differential centrifugation and a filtration step, as
previously described. Briefly, 3–4-day culture medium
was centrifuged at 300 × g for 10 min to remove cells.
The supernatant was further centrifuged at 16,500 ×
g for 20 min. Subsequently, the supernatant was cen-
trifuged at 120,000 × g for 3 h (Type 45 Ti rotor,
Beckman Coulter). The samples were dissolved in
PBS, and the protein concentration was measured by
a BCA Protein assay kit (Pierce™, Thermo Fisher
Scientific, Waltham, MA, USA). We used this type of
exosome preparation in all studies unless indicated.
Using density cushion
In some experiments (Figure 6 and Supplementary
Figure 4), exosomes were collected on 10–30% iodix-
anol interphase cushions instead of direct pelleting
(Supplementary Figure 3a). After collecting the exo-
somes from the interphase, they were bottom loaded
onto an iodixanol flotation gradient (0, 20, 22, 24, 26,
28, 30, 50, 60%) followed by subsequent flotation by
centrifuging at 182,300 × g for 16 h using an SW40-Ti
swinging bucket rotor. Purified exosomes were col-
lected from fractions between layers 20% and 22%
after centrifugation.
Reversed cell migration and invasion assay
The migration capacity and invasiveness of MSCs were
evaluated using a 48-well Boyden chamber
(Neuroprobe, Gaithersburg, MD, USA). In some
experiments, MSCs were pre-incubated with mast cell-
derived exosomes for 48 h before seeding and referred
to as exosome-treated MSCs. Five thousand cells/well
were seeded to the bottom compartment and were
separated from the upper chamber by a polycarbonate
membrane with 8 µm pores. The membrane was pre-
coated with 0.1% gelatin or 200 μg/ml ECM Gel from
Engelbreth-Holm-Swarm murine sarcoma (Sigma-
Aldrich). After being seeded, cells were allowed to
adhere onto the membrane by inverting the chamber
assembly upside down for 3.5 h. Later the chamber was
placed in the correct orientation and FBS was added in
the upper compartment. After incubation for 12 h at
37°C, the membrane was removed and cells on the
migrated sides were fixed in methanol (10 min) and
stained with Giemsa (Histolab, Västra Frölunda,
Sweden) for 1 h. Cells from the non-migrated side
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were wiped off before imaging. Three fields at 40×
magnifications were imaged. For the migratory inhibi-
tion experiments, MSCs were incubated with 100 nM
of LY2157299 (Selleckchem, Munich, Germany), which
is an inhibitor of TGFβ type-1 receptor. Each analysis
was performed in triplicate.
Scratch assay
Human MSCs were grown to 70–80% confluence in
6-well plates, and the monolayer cells were scratched
with a 1 ml pipette tip across the centre of the wells.
After the cells had been washed with PBS, MEM plain
medium with or without exosomes (100 μg/ml) was
incubated with MSCs. Migratory cells from the
scratched boundary were imaged after various time
points.
Gelatin zymography
The supernatant from MSCs, cultured with or without
mast cell-derived exosomes, was collected at 24 and 48
h and electrophoresed onto zymogram precast gels
containing 10% gelatin (BioRad Laboratories,
Hercules, CA, USA) with 5× non-reducing loading
buffer (Sigma Aldrich). Gels were re-natured with
2.5% Triton X-100 (Sigma Aldrich) for 1 h at room
temperature and then incubated in development solu-
tion (50 mM Tris (pH 7.4), 5 mM CaCl2, 200 mM
NaCl) at 37°C overnight. Gels were stained (coomassie
brilliant blue) and destained (30% methanol and 10%
acetic acid) until the clear bands appeared. Finally, the
gel was incubated with stop solution (2% acetic acid).
Band intensity was quantified using ImageJ software.
Sample digestion and nanoLC-MS analysis to
identify membrane proteins on exosomes
Proteomic analyses were performed at The Proteomics
Core Facility at the Sahlgrenska Academy, University
of Gothenburg. The samples in approximately 100 μl of
PBS were lysed by the addition of sodium dodecyl
sulfate (SDS) to a final concentration of 2% SDS and
50 mM triethylammonium bicarbonate (TEAB). Total
protein concentration was determined with the Pierce™
BCA Protein Assay (Thermo Scientific). Aliquots con-
taining 50 μg of each sample were digested with trypsin
using the filter-aided sample preparation (FASP)
method [59]. Briefly, protein samples were reduced
with 100 mM dithiothreitol at 60°C for 30 min, trans-
ferred to 30 kDa MWCO Pall Nanosep centrifugal
filters (Sigma-Aldrich), washed with 8M urea solution
repeatedly, and alkylated by addition of methyl
methanethiosulfonate to a final concentration of
10 mM. Digestion was performed in 50 mM TEAB,
1% sodium deoxycholate (SDC) overnight at 37°C after
addition of trypsin (Pierce Trypsin Protease, MS
Grade, Thermo Fisher Scientific) in a ratio of 1:100
relative to the amount of protein. An additional por-
tion of trypsin was added and incubated for another 2
hours followed by the collection of the peptides by
centrifugation. Samples were acidified to pH 2 by addi-
tion of TFA to precipitate SDC.
Samples were desalted using PepClean C18 spin
columns (Thermo Fisher Scientific) according to the
manufacturer’s guidelines prior to analysis on a Q
Exactive mass spectrometer (Thermo Fisher Scientific)
interfaced with Easy nLC 1000 liquid chromatography
system. Peptides were separated using an in-house
constructed C18 analytical column (200 × 0.075 mm
I.D., 3 μm, Dr. Maisch, Germany) using a gradient
from 5% to 25% acetonitrile in 0.1% formic acid for
75 min and finally from 25% to 80% acetonitrile in
0.1% formic acid for 5 min at a flow of 200 nL/min.
Precursor ion mass spectra were recorded in positive
ion mode at a resolution of 70,000 and a mass range
of m/z 400 to 1600. The 10 most intense precursor ions
were fragmented using HCD at a collision energy of 27,
and MS/MS spectra were recorded in a scan range
of m/z 200 to 2000 and a resolution of 35,000. Charge
states 2 to 6 were selected for fragmentation, and
dynamic exclusion was set to 30 s. Samples were re-
analyzed with exclusion lists of m/z values of the iden-
tified peptides at 1% FDR with a 10-min retention time
generated after database searching of previous LCMS
runs (as described below).
Data analysis was performed utilizing Proteome
Discoverer version 1.4 (Thermo Fisher Scientific) against
Human Swissprot Database version March 2015 (Swiss
Institute of Bioinformatics, Switzerland). Mascot 2.3.2.0
(Matrix Science) was used as a search engine with
a precursor mass tolerance of 5 ppm and a fragment
mass tolerance of 100 mmu. Tryptic peptides were
accepted with one missed cleavage and methionine oxi-
dation was set as the variable modifications and cysteine
alkylation as the static modification. The detected peptide
threshold in the software was 1% False Discovery Rate by
searching against a reversed database, and identified pro-
teins were grouped by sharing the same sequences to
minimize redundancy.
Immunofluorescence microscopy
The seeded cells after treatment were wash and fixed with
3.7% paraformaldehyde at room temperature for 10 min,
permeabilized for 5 min with 0.2% Triton X-100, and
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washed and blocked for 1 h in 3% BSA. Cells were stained
with primary antibody for 1 h and washed with PBS for
three times. Finally, incubation with GFP-AF-488 anti-
body (1:200, A21311, Life Technology) was performed
for 1 h at RT. After three washes with PBS, the cells were
further stained with DAPI (SigmaAldrich) and coverslips
were mounted using Gold anti-fade mounting reagent
(Invitrogen, Carlsbad, CA, USA) and observed under
a fluorescence light microscope (Axio Observer, Zeiss,
Oberkochen, Germany). The above-mentioned staining
protocol was also performed to stain MSCs for nuclear
SMAD2 (s-20, Sc-6200, Santa Cruz Biotechnology, CA,
USA) after exosome treatment, Nuclear expression of
SMAD2 was evaluated with the Velocity image analysis
software (PerkinElmer, Chicago, IL, USA).
Transmission electron microscopy
To describe the nano-structures in exosomes derived
from primary human mast cells, we performed trans-
mission electron microscopy (TEM). Isolated exosomes
described in the section “Isolation of exosomes (i)”
were bottom loaded and floated on an iodixanol
(OptiPrep®) density gradient (0%, 20%, 22%, 24%,
26%, 28%, 30%, and 50%) and centrifuged at 182,300
× g for 16 h (SW40-Ti Rotor) to separate them from
free proteins. Nine different iodixanol fractions were
collected, and samples from fraction no. 2 were sub-
jected to TEM as described in our previous study [57].
Labelling of exosomes and uptake
Exosomes were obtained as described in the “Isolation
of exosomes (i)” section and were labelled with the
PKH67 Green Fluorescent Cell Linker Kit (Sigma
Aldrich) as per the manufacturer’s protocol and as
described previously [57] with modifications in the
removal of unbound dyes. The labelled exosomes
were loaded at the bottom of an iodixanol cushion
(0%, 20%, 30%, and 50%) and centrifuged at 182,300
× g for 4 h (SW40-Ti Rotor) to separate them from the
free unbound dye. The lipid-labelled exosomes were
collected from the interphase between 20% and 30%
and washed in PBS and centrifuged at 120,000 × g for
3.5 h (Type 45 Ti rotor, Beckman Coulter). Washed
exosomes were incubated with the MSCs (4,000 cell/
cm2) for 4 or 16 h at 4°C or 37°C. FACS was per-
formed on the cells to determine the uptake rate. For
visualization, exosomes were incubated with MSCs for
4 h, fixed in 3.7% paraformaldehyde, stained with
DAPI, and imaged under a fluorescence light micro-
scope (Axio Observer, Zeiss).
Fluorescence correlation spectroscopy
Freshly isolated exosomes from HMC-1 cells were
labelled either alone with optimized concentration of
DiO (Life Technologies, Thermo Fisher Scientific) lipid
dye (0.22 µg/ml), TGFβ-1-Alexa Fluor-647 (1:50) and
CD63-Phycoerythrin (1:20), or a combination of two
labels (DiO/TGFβ-1-AF647 or TGFβ-1-AF647/CD63-
PE or DiO/CD63-PE). All labelled EVs were purified
from the free label using an iodixanol density cushion
as described in the “Labeling of exosomes and uptake”
section. Washed pellets were analyzed by dual-colour
Fluorescence Cross-Correlation Spectroscopy (FCCS).
Two different FCS/FCCS setups were used. The first
was a confocal microscope (FCS-equipped Zeiss 780)
fully equipped for FCS and FCCS measurements. On
this setup, we used mainly the 488 nm and 633 nm
laser lines, but to some extent also the 514 nm and the
561 nm laser lines. The 488 nm laser line resulted in
a focus radius ω0 = 0.25 μm and a volume of 0.45
femtoliters (fL), while the 633 nm laser line gave
a focus with ω0 = 0.29 μm and a volume of 0.65 fL.
Analysis of the FCS/FCCS curves was performed using
the Zeiss Zen software. In addition, a home-built FCCS
setup based on a 488 nm line (Argon laser, Lasos
GmbH) and a 594 nm line (HeNe laser, Laser2000
GmbH) was used. In this setup, the 488 focus had ω0
= 0.36 μm and a volume of 1.5 fL, while the 594 focus
had ω0 = 0.39 μm and a volume of 2.4 fL. Emission
filters ET535/70 and ET700/75 (Chroma) were used.
The correlator was an ALV-5000 (ALV GmbH).
Analysis was performed using the ALV-5000 software
and Origin 9.1 (Origin lab Corporation, USA).
Apoptosis induction and inhibition
HMC-1 cells were cultured in cell culture medium
supplemented with either 1 mM hydrogen peroxide
(Sigma) or with 20 µM Z-VAD-FMK (Invivogen, CA,
USA) for 72 h before conditioned supernatant was
taken for exosomes isolation as described in
“Isolation of exosomes–using density cushion”.
TGFβ-1 detection on exosomes
The amount of TGFβ-1 in the supernatant of MSCs
and on the HMC-1 cell line-derived exosomes was
determined using a TGFβ-1 ELISA Ready-SET-Go kit
(eBioscience, Affymetrix) according to the manufac-
turer’s instructions. To determine the forms of TGFβ-
1, we either included or did not include the acidifica-
tion step (HCl) to measure total and active TGFβ-1
levels, respectively. To measure the relative level of
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TGFβ-1 on primary human matured mast cells on
captured CD63+ exosomes, we used a high-sensitivity
chemiluminescence-based detection system (Roche
Molecular Systems, IN, USA). For this experiment, we
used a CD63 antibody to coat the ELISA plate, and the
remaining antibodies were from the TGFβ-1 ELISA
Ready-SET-Go kit.
Quantitative real-time polymerase chain reaction
Total RNA was isolated fromMSCs using the miRCURY™
RNA isolation kit for cell and plant (Exiqon, Vedbaek,
Denmark). TURBO™ DNase treatment and removal
reagents (Ambion, Life Technologies) were used to remove
contaminating DNA from RNA preparations, and the
concentration and purity of RNA were evaluated by
NanoDrop (Thermo Scientific). cDNA was synthesized
from 200 ng total RNA by using the iScript™ cDNA
Synthesis Kit (BioRad) according to the manufacturer’s
protocol. Quantitative real-time PCR was performed with
SsoAdvanced™ Universal SYBR® Green Supermix on
a BioRad CFX96™ system. cDNA was denatured for 30
s at 95°C and then subjected to 40 cycles of 95°C for 15
s and 60°C for 30 s. The primers were obtained from Sigma
(KiCqStart® primers): TGFB1, SMAD2, MMP2, and EF1.
Data were collected by software and analyzed. EF1 was
used to normalize the data, and the 2T
−ΔΔC method was
used to determine relative changes in gene expression.
Western blotting
MSCs were lysed in RIPA buffer (Cell Signaling
Technology ST, Danvers, MA, USA), 1 mM PMSF,
1 mM Sodium orthovanadate, and 1 mM Sodium
fluoride. Twenty micrograms of protein lysate were
subjected to SDS-PAGE and transferred onto nitrocel-
lulose membranes. Membranes were blocked with 5%
non-fat milk (or 5% bovine serum albumin for phos-
pho-antibodies) in TBS containing 0.05% Tween-20
and incubated with primary antibodies at 4°C over-
night and HRP-conjugated secondary antibodies
(1:10,000 dilution, NA931V, NA9340, NA9310V, GE
Healthcare) for 1 h at room temperature. The proteins
were detected with the ECL Prime Western Detection
(GE Healthcare) according to the manufacturer’s pro-
tocol. The antibodies used were as follows: β-actin
(1:10,000 dilution, 13E5, #4970S, Cell Signaling
Technology), TSG101 (1:1,000 dilution, ab83, Abcam),
CD81 (1:1,000 dilution, sc9158, Santa Cruz
Biotechnology), EEA1 (1:1,000 dilution, sc33585,
Santa Cruz Biotechnology), LAMP1 (1:1,000 dilution,
ab24170, Abcam), FLAG-antibody (1:5,000 dilution,
#M2, F3165, Sigma), Flotillin-1-antibody (1:1,000
dilution, #sc74566, Santa Cruz Biotechnology),
pSMAD2 (1:500 dilution; Thr220; #sc135644; Santa
Cruz Biotechnology), SMAD2 (1:1000 dilution; S20 ;
Santa Cruz Biotechnology), and 6x-His Tag (1:1,000
dilution; #MA1-21315-A488; HIS.H8 Thermo
Scientific).
Particle number and size measurements
The sizes and concentrations of exosomes were mea-
sured using ZetaView® PMX110 (Particle Metrix,
GmbH, Meerbusch, Germany). Each exosomes sample
was diluted in PBS in a range of 1:1,000 ~ 1:5,000 and
injected into the instrument. The chamber temperature
was maintained automatically. Measurements were
obtained in triplicate, and each individual result was
obtained from two stationary layers with five measure-
ments in each layer. The sensitivity of the camera was
fixed at 70 in all measurements. Data were analyzed
using ZetaView analysis software version 8.2.30.1 with
a minimum size of 5 nm, a maximum size of 1,000 nm,
and a minimum brightness of 20.
Lineage differentiation of MSCs
MSCs treated with 100 μg/ml exosomes for 48 h were
cultured in lineage differentiation medium for 15 days as
per the manufacturer’s instructions (Human mesenchy-
mal stem cell functional identification kit, SC006, R&D
Systems). Lineage-specific markers for adipocytes
(FABP4, Oil red O) and osteocytes (Osteocalcin,
Alizarin Red) were probed and analyzed in the respective
cells as described in previously published guidelines [60].
TGFβ-1 knockout
Stable doxycycline-regulated Cas-9-expressing human
mast cells (HMC-1) were generated by cloning a pCW-
Cas9–containing plasmid (Gift from Eric Lander and
David Sabatini; Addgene Plasmid #52961). Target
gRNA (ACCAAAGCAGGGTTCACTAC) against the
human TGFbeta-1 gene was cloned into the plasmid
backbone of pLX-sgRNA (Gift from Eric Lander and
David Sabatini (Addgene Plasmid #50662)) with
Reverse (R1) primer 5ʹ-GTA GTG AAC CCT GCT
TTG GTC GGT GTT TCG TCC TTT CC-3ʹ and
Forward (F2) primer 5ʹ-GAC CAA AGC AGG GTT
CAC TAC GTT TTA GAG CTA GAA ATA GCA A-3ʹ.
The gRNA was chosen from library B of the
Human GeCKO v2 Library (2-Plasmid System –
lentiGuide-Puro; cat #1000000049). The pLX-
TGFB1 gRNA-carrying plasmid was expanded and
purified from chemically competent Escherichia coli
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(MAX Efficiency® Stbl2, Life Technology) and
transfected into Cas-9-HMC-1 cells with doxycy-
cline (0.5 μg/ml). Knockout clones were selected
using limiting dilution of cells under blasticidin.
Efficiency of knockout was tested by estimating
the level of TGFβ-1 protein in knockout cell lysate
(Supplementary Figure 10).
Localization of exosomes and isolation of
organelles
Isolated exosomes (as described in the method section
under “Isolation of exosomes”) were loaded at the bottom
of an iodixanol gradient (0%, 20%, 22%, 24%, 26%, 28%,
35%, and 50%) and centrifuged at 182,300 × g for 16
h (SW40-Ti Rotor) to purify the exosomes from the
20–22% layer of the iodixanol gradient. The surfaces of
the iodixanol-purified exosomes (10 μg/ml) were bioti-
nylated by incubating them with EZ-Link Sulfo-NHS-
Biotin (Thermo Scientific) as per the manufacturer’s
recommendation. Free biotin was removed from biotiny-
lated exosomes via dialysis by sequentially changing PBS
after 2 h (room temperature), overnight (4°C), and finally
for 2 h (room temperature). These biotinylated exosomes
were later incubated with HEK293T cells for 60 min, and
organelles were isolated from these cells using a lysosome
enrichment kit (Thermo Scientific) following the manu-
facturer’s guidelines with further modification to enrich
lysosomes and endosomal compartments from the orga-
nelle pool. Briefly, 100 mg HEK293T cells were mixed
with reagent “A” with short vortexing followed by lysis
via sonication pulses (25–30 bursts, 2 min each, 4°C).
This suspension was mixed uniformly with an equal
volume of reagent “B” and centrifuged (500 × g, 10 min,
4°C) to collect the supernatant. This supernatant was
loaded onto the top of an iodixanol density gradient
(17%, 20%, 23%, 27%, and 30%) and centrifuged at
145,000 × g for 2 h at 4°C. After the first round of
ultracentrifugation, the first two fractions (green and
red, Figure 5(c)) were collected and bottom loaded in
two separate tubes with different iodixanol densities
(18%, 20%, 22%, 22%, 24%, 26%, 28%, 30%, 35%, and
50%) for the second round of ultracentrifugation
(182,300 × g, SW40-Ti Rotor, 16 h, 4°C). The fractions
were collected from top to bottom (1 ml each for 10
factions) and subjected to western blotting analysis of
lysosome (LAMP1) and endosome (EEA1) enrichment
markers to define the distribution of the density. From
these fractions, the lysosome-enriched fraction (LEF;
fraction 2–3) and the endosome-enriched fraction (EEF;
fraction 7–9) were used to locate the biotinylated exo-
somes (Figure 5(d)).
In order to locate the biotinylated exosomes the level
of TGFβ-1 protein inproteins in these fractions (LEF and
EEF), two complementary approaches were used. First,
LEF and EEF were both incubated separately with strep-
tavidin-coated beads and probed for total bound protein
or EEA1 and LAMP1 antibody (Supplementary Fig 12).
In the second approach, LEF and EEF fractions were both
incubated separately either with EEA1 or LAMP1-coated
beads and probed to detect biotinylated proteins in
a respective fraction (Figure 5(f)).
SMAD3 phosphorylation assay
Activation of SMAD3 in exosomes-treated MSCs was
detected by using Homogeneous Time Resolved
Fluorescence (HTRF®)-based detection of phosphorylated
SMAD3 at the Ser423/425 residues using the Cisbio
Bioassay kit (Codolet, France). Briefly, 15,000 MSCs were
seeded in a 96-well plate overnight. The cells were then
serum deprived for 2 h before any treatments.
Subsequently, the cells were exposed to either exosomes
derived from mast cells (30 µg/ml) or free TGFβ-1 (10 ng/
ml) for 30 min. The cells were then washed and lysed, and
the estimation of pSMAD3was performed according to the
Cisbio Bioassay guidelines (Part no #63ADK025PEG).
Removal of surface TGFβ-1
TGFβ-1 present on the surface of exosomes was
removed by treating the crude exosomes (obtained
with the iodixanol cushion) with either 0.125% trypsin
(Hyclone Laboratories, Logan, UT, USA) or 30 U/ml of
Bacteroides heparinase II (New England Bio Labs, Inc.
USA) to remove surface protein or surface heparin and
heparin sulfate, respectively. These samples were bot-
tom loaded and refloated on an iodixanol density gra-
dient as described in “Isolation of exosomes: using
density cushion ” and analyzed for the presence of
TGFβ-1 (total and active) and CD81. To inhibit cellular
glycosaminoglycan, we treated HMC-1 cells with 1 mM
of the pharmacological inhibitor p-nitrophenyl-beta
-D-xylopyranoside (pNP-Xyl) for 72 h, and exosomes
were isolated from the conditioned medium.
In vitro interaction of LAP with active-TGFβ-1 and
cellular uptake
Interaction of Latent Associated Peptide (LAP) with
active-TGFβ-1 was determined by the ability of LAP-
TGFβ-1 complex to migrate during gel-electrophoresis
in non-reducing condition. Briefly, 200 ng of recombi-
nant LAP protein (#246-LP, R&D system) was incubated
with 50 ng, 100 ng and 200 ng of active-TGFβ-1 (TGFβ-
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1-Standard; component of TGFβ-1 ELISA kit;
eBioscience, Affymetrix) for 30 min at 37°C. This com-
plex was allowed to separate on PAGE and the gel was
stained with silver staining reagents as per manufacturer
instruction (Pierce™ Silver Stain Kit # 24612, Thermo
Fisher Scientific). To determine the cellular uptake of
LAP by MSC cells, we first incubated 1000 μg of HMC-
1 derived-exosomes with 10 μg of Histidine-tagged
recombinant human LAP (TGFβ-1) (#LAP-H5245,
Acrobio systems) for 60 min at RT. This complex was
loaded at the bottom of iodixanol density gradient (10%,
24%, 30%, and 50%) and centrifuged overnight at 182,300
×g for 16 h using an SW40-Ti rotor. Interphase exosomes
were collected from fractions between layers 10%-24%
and was used for uptake analysis. The localization of
histidine tagged human LAP (TGFβ-1) in MSCs was
determined by anti-histidine antibody-AF488 (#MA1-
21315-A488, Invitrogen) using fluorescence microscope.
In vitro exosome acidification assay
HMC-1–derived exosomes from 150 ml conditioned
medium were subjected to different pH conditions (pH
= 7, 6, 5, 4) for 60 min at 37°C. These preparations were
used to collect EVs by re-centrifuging at 52,000 rpm for
60 min in a TLA-100.3 rotor (Beckman Coulter, CA,
USA). The pelleted EVs were subjected to total-TGFβ-1
ELISA (Figure 6(d)) as described earlier.
Statistical analysis
Analyses were performed using the Student’s t-test (two-
tailed). Data presented are mean±sem. and P < 0.05 was
considered statistically significant.
Results
TGFβ-1 is present on the surface of mast cell-
derived exosomes
It is known that the surface and lumen of exosomes
can harbour multiple bioactive molecules [25]. For
example, an earlier study from our group described
the presence of bioactive c-KIT receptor on mast cell-
derived exosomes, and this functional receptor is trans-
ferred between cells [3]. With the intention to profile
other bioactive molecules to determine the function of
these exosomes, we first performed membrane proteo-
mics of the mast cell line HMC-1-derived exosomes.
This proteomics approach reduces extra- and intra-
vesicular proteins, but enriches membrane proteins
and can, therefore, detect various low-abundance
bioactive proteins that are not detected in standard
proteomics assays [26]. In total, we identified 1743
proteins (Supplementary Table 1), of which 504 were
membrane-proteins, including several receptors such
as TGFβ and insulin receptors. Further analysis also
confirmed the presence of c-KIT receptor, supporting
our previous study [3]. Interestingly, we also detected
cytokines, including MIF, TIMP1, and TGFβ-1, mole-
cules that are otherwise rarely identified with mass
spectrometry of biological samples due to their low
abundance (Supplementary Table 1). Multiple
approaches were taken to validate the presence of
TGFβ-1 on the vesicles. Firstly, we used enzyme-
linked immunosorbent assay (ELISA) to confirm the
presence of TGFβ-1 in the vesicle-rich floating fraction
of a density gradient of HMC-1 cell line-derived exo-
somes [density of approximately between 1.08 and 1.16
g/ml (Figure 1(a))]. The presence of TGFβ-1 was coin-
cident with the commonly used exosome-enriched pro-
tein TSG101 and CD81 as detected with western blot
(Figure 1(a), lower panels). Similarly, the floating frac-
tions of exosomes derived from from primary mast
cells also contained TGFβ-1, again shared similar den-
sity as with cell line-derived EVs (Supplementary
Figure 1). However, for the primary mast cell-derived
exosomes the levels of TGFβ-1 in the high-density
fraction were higher than in the low-density fractions.
Exosomes released by primary cells had comparable
size and structure as the cell line-derived exosomes as
determined by electron microscopy, nanoparticle
tracking analysis and they expressed exosomes-
enriched proteins such as CD63, CD81, and CD9
(Supplementary Figure 2). However, the exosomes
from primary mast cells carried relatively lower levels
of the exosomes-enriched surface CD81 and CD9
(Supplementary Figure 2F) than the HMC-1 cell line-
derived vesicles (Supplementary Figure 2E).
TGFβ-1 exists in an active and in an inactive form,
and they can be discriminated by the use of hydrochlo-
ric acid (HCl) acidification of the samples, after which
TGFβ-1 ELISA is performed (Figure 1(b), upper panel).
We observed that approximately 40% of the total
TGFβ-1 on the exosomes was in the active form
(Figure 1(b), lower panel), and 60% in the inactive
form. Finally, we performed a sandwich ELISA to
quantify the amount of TGFβ-1 associated with exo-
somes bound to anti-CD63-coated beads. We could
detect approximately 12 pg of total TGFβ-1 on 30 µg
of CD63-positive exosomes from HMC-1 cells, out of
which 7.1 pg was in the active form (Figure 1(c)). In
addition, the co-association of TGFβ-1 with an exo-
some was observed by fluorescence correlation spectro-
scopy (FCS). Specifically, we found that the signals for
TGFβ-1 and the exosome-enriched surface protein
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CD63 were co-localized in the same time lapse and had
the same diffusion time in the FCS analysis (Figure 1
(d)), which strongly suggests that they are co-localized
on the same individual vesicle. With this method, we
determined that approximately 17% of the CD63+
vesicles were also positive for surface TGFβ-1.
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Figure 1. TGFβ-1 co-localizes with exosomes. (a) Exosomes isolated from HMC-1 were floated on iodixanol density gradients,
and the expression of TGFβ-1 (ELISA) and the exosome-enriched proteins TSG101 and CD81 (immunoblotting) were
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Additionally, we used sandwich ELISA to detect the
levels of TGFβ-1 on CD63+ vesicles using capture anti-
body against CD63 in various HMC-1 fractions after
iodixanol density gradient separation (Figure 1(e)).
To exclude the possibility that TGFβ-1 was associated
with the exosomes mechanically through the isolation
procedure (ultracentrifugation), we also used a non-
pelleting approach for exosomes isolation. Specifically,
exosomes were collected in the interphase between 10%
and 30% after an iodixanol density cushion centrifuga-
tion and were further floated on a density gradient and
collected at ~1.08 g/ml density (Supplementary Figure
3a). Even though the viability of the HMC-1 cells used
for exosomes isolation was >99% using a trypan blue
assay, we further investigated the possibility of back-
ground apoptosis contributing to the presence of TGFβ-
1. Briefly, the HMC-1 cells were treated with an apoptosis
inhibitor (Z-VAD-FMK) or inducer (H2O2) and exo-
somes were collected using the non-pelleting approach
(Supplementary Figure 3A-B). When apoptosis was
induced (H2O2), an increased number of particles could
be isolated; however, no significant increase in exosome-
associated TGFβ-1 was observed (Supplementary Figure
3c-d). Similarly, when apoptosis was inhibited (Z-VAD-
FMK), no significant reduction of exosomes-associated
TGFβ-1 was observed (Supplementary Figure 3d).
Furthermore, the presence of surface CD9, CD63, and
CD81 along with luminal flotillin-1 was confirmed in
TGFβ-1–captured vesicles (Supplementary Figure 3e-f).
Taken together these experiments conclusively show that
TGFβ-1 is associated with exosomes on their surface and
is not introduced to the exosomes during the ultracen-
trifugation or by cell death.
Glycan-based association of inactive TGFβ-1 with
exosomes
To determine how the different forms of TGFβ-1 are
associated with the exosomes surface, we first
obtained purified exosomes with the non-pelleting
approach (Supplementary Figure 3a). Exosomes
were treated with trypsin (0.125%) and again floated
on a density gradient. The inactive form of TGFβ-1
was efficiently removed by the trypsin treatment,
while the active form remained associated with the
exosomes (Figure 2(a)). Interestingly, the active form
of TGFβ-1 could very well be associated with the
TGFBR1 that we identified earlier in membrane pro-
teomics analysis (Supplementary Table 1). Indeed, we
confirmed our findings from the exosome membrane
proteomics by immunoblotting analysis of exosomes
of TGFBR1, a known ligand of active-TGFβ-1
(Supplementary Figure 4).
Inactive TGFβ-1 contains the latent-associated peptide
(LAP), and it is known that the LAP-TGFβ-1 complex can
associate with the extracellular matrix by binding to
heparan sulfate glycoprotein (HSPGs) [27,28]. To deter-
mine whether HSPGs such as heparin and heparan sulfate
are important for the association of LAP-TGFβ-1 to the
exosome-surface, exosomes were treated with heparinase-
II. When exosomes were treated with heparinase-II, only
inactive-TGFβ-1 was removed from the exosome, and no
significant alterations were observed in the active-TGFβ-1
levels (Figure 2(b)). Additionally, trypsin treatment slightly
reduced the surface protein on the exosome surface (CD81)
compared to the luminal β-actin indicating that the EVs
remain intact during the treatments (Figure 2(c)).
However, heparinase-II does not have an effect on any
membrane and luminal exosomes (Figure 2(c)). HSPGs
are present on the outside of the cell membrane, and
HSPGs such as syndecan and glypican have been reported
to be markers of EVs [29,30]. To determine whether the
association of HSPGs with TGFβ-1 is related to active
cellular proteoglycan synthesis, we treated the HMC-1
cells with the inhibitor p-Nitrophenyl-β-D-xylopyranoside
(pNP-Xyl). Exosomes isolated from pNP-Xyl-treated cells
showed a significant decrease in total TGFβ-1, indicating
a novel mechanism by which TGFβ-1 can be associated
with the surface of exosomes (Supplementary Figure 5a).
We then evaluated whether the reduction seen is due to the
change in inactive or active TGFβ-1. Exosomes isolated
from pNP-Xyl treated showed a lowering of inactive
TGFβ-1 with no significant changes in active TGFβ-1
(Figure 2(d), Supplementary Figure 5b). Taken together
these findings suggest that the inactive form of TGFβ-1 is
associated with exosomes via heparin and heparan sulfate
sensitive glycoproteins.
Mast cell-derived exosomes enhance the migratory
function of MSCs
During inflammation, immune cells are known to mod-
ulate the phenotype of recipient cells by various secreted
factors, including exosomes [31,32]. We hypothesize that
exosomes from mast cells induce phenotypic changes in
humanMSCs. HMC-1 exosomes were efficiently taken up
by primary human MSCs in a time- and temperature-
dependent manner, which suggests that vesicle uptake is
a biologically active process (Supplementary Figure 6).
Adding exosomes derived fromHMC-1 as well as primary
mast cells to the MSCs induced an elongated morphology
in the MSCs (Figure 3(a), Supplementary Figure 7a) and
increased wound healing activity (Figure 3(b),
Supplementary Figure 7b) but did not alter the ability of
the MSCs to differentiate because they still could differ-
entiate into both adipocytes and osteocytes
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(Supplementary Fig. 8). Enhanced migratory activity of
MSCs upon exosomes stimulation was also associated
with the increase in transcripts of matrixmetalloproteinase
(MMP-2 and MMP-9) mRNA in cells and with increased
secretion of MMP-2 and MMP-9 proteins into the cell
culture supernatant and was associated with the increased
gelatinolytic activity (Figure 3(c,d)). It has previously been
shown that multiple growth factors can influence MSC
migration by regulating signalling cascades [33].We there-
fore used fetal bovine serum (FBS) as a pan-
chemoattractant in the next experiment and could show
that exosome-treated MSCs have an increased and dose-
dependent migratory tendency towards the FBS compared
to non-treated MSCs (Figure 3(e)). Collectively, these
results show unequivocally that mast cell-derived exo-
somes enhance the migration of MSCs in vitro.
TGFβ-1 on the surface of exosome induces
activation of SMAD in MSCs
It has earlier been described that soluble TGFβ-1 can
stimulate MSC migration [34], and because we
observed that TGFβ-1 is present on the membrane of
exosomes, we set out to determine whether this mole-
cule is responsible for the observed migration activity
of the cells. Importantly, SMADs are a family of pro-
teins that are involved in signal transduction and tran-
scriptional regulation [35], and SMAD2 is activated in
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response to TGF-β signalling and might be involved in
MSC migration [36]. Indeed, we observed increased
phosphorylation of SMAD2 in MSCs after exosome
exposure (Figure 4A). Furthermore, the ratio between
nuclear and cytoplasmic SMAD2 in MSCs increased
following exosomes treatment, indicating that exo-
somes induced nuclear translocation of this
transcription factor (Figure 4(b,c)). To determine
whether the signalling is restricted to SMAD2, or
whether any other SMADs were regulated, we deter-
mined the phosphorylation of SMAD3 using
a fluorescence resonance energy transfer (FRET)
based assay in recipient MSCs (Supplementary Fig. 9).
Consistent with activation of SMAD2, we also observed
b
48 h24 h  
MMP9
MMP2
0       10     100 
Exo (HMC-1)
(μg/ml) 0       10     100
d
MSCs only 
a
MSCs + Exo (HMC-1) MSCs only
24
 h
48
 h
MSCs +
Exo (HMC-1)
e
Fo
ld
 c
ha
ng
e 
in
 m
R
N
A
w.
r.t
 u
nt
re
at
ed
 c
el
l 48  h
24 h
Exo(HMC-1)
(μg/ml)
10
5
0
30
60
90
10       100       10       100
MMP9             MMP2
c
FBS (%)
** 
** 
** 
0            1          10
N
um
be
r o
f c
el
ls
 / 
fie
ld MSC only
MSC + Exo (HMC-1)
40
20
0
60
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a time- and dose-dependent increase in Tgfb1 mRNA
transcript following exposure to exosomes (Figure 4
(d)). This suggests that exosomes enhance Tgfb1
expression in MSCs, most likely via SMAD2 signalling.
This is consistent with a previous study documenting
that soluble TGFβ-1 regulates its own expression in an
autocrine manner [37].
To determine whether exosome-associated TGFβ-1 is
responsible for the observed enhanced migration and
TGFβ-1signaling in MSCs, we first isolated exosomes
from TGFB1 knockout HMC-1 cells (doxycycline-
inducible CRISPR/Cas-9 system; Supplementary Fig.
10a-b). Indeed, exosomes derived fromTGFβ-1 knockout
mast-cells resulted in reduced phosphorylation of
Figure 4. Exosomes activate SMAD signalling in human mesenchymal stem cells. (a) Exosomes (100 µg/ml) activate the TGFβ-1
signalling axis by phosphorylation of SMAD2 as identified by immunoblotting at different time points. (b,c) Activation is visualized
by immuno-fluorescent imaging of the translocation of SMAD2 into the nucleus (b) and is quantified by the relative intensity
measurement (c) in MSCs 30 min after exosome exposure. (d) Activation of transcripts downstream of SMAD2, such as TGFB1, was
evaluated in MSCs at 24 h and 48 h after exosome exposure. (e,f) Exosomes from TGFβ-1 knockout HMC-1 cells were used to induce
phosphorylation of SMAD2 in MSCs as measured using immunoblotting (e) and as measured by their capacity to induce migration
towards FBS (f). (g) Migration capacity of MSCs towards FBS after exosome treatment was also evaluated in the presence of
a blocking antibody against TGF-β-1, 2, 3 using a Boyden chamber migration assay. (h) Secretion of TGFβ-1 in MSCs was measured
in the presence of the TGFR-1 receptor blocking agent LY2157299 during exposure to exosomes at 24 h and 48 h. Data are
presented as means ± SEM; n = 3; * p ≤ 0.05, ** p ≤ 0.01.
12 G. V. SHELKE ET AL.
ed f
a
U
nt
re
at
ed
 
E
xo
DAPI SMAD2
b
h
5      15     30   min 
pSMAD2 
β-actin
Exo
g
Fo
ld
 c
ha
ng
e 
in
 tg
fβ
-1
m
R
N
A
 
w
.r.
t u
nt
re
at
ed
 c
el
ls
 
c
**
R
el
at
iv
e 
in
te
ns
ity
 o
f 
nu
cl
ea
r S
M
A
D
2 
2
1
0
3
48 h
24 h
- + +    - + +    - + + Exo
Anti-TGFβ-1,2,3
* *
**
N
um
be
r o
f c
el
ls
 / 
fie
ld
0
1
10
FBS %
30
20
10
40
50
0
Exo (µg/ml)
10          100
30
20
10
40
50
0
FBS (%)
N
um
be
r o
f c
el
ls
 / 
fie
ld
50
25
75
100
10            100
0
**
Untreated 
Exo
Exo-TGFB1-KO
pSMAD2 
β-actin
- - +    - - +    - - +
- +   +   - +   + Exo
LY2157299 
S
ec
re
te
d 
TG
Fβ
-1
 (p
g/
m
l)
48 h
72 h**
**300
200
100
0
- - +       - - +
SMAD2 in recipient MSCs compared to exosomes from
control cells (Figure 4(e)), as well as reduced migration
towards the pan-chemoattractant FBS (Figure 4(f)). To
further confirm the role of exosomes-surface TGFβ-1, we
pre-incubated exosomes with a pan-TGFβ-neutralizing
antibody that blocks the TGFβ-1, 2, 3 interaction with
its receptor. The TGFβ-neutralized exosomes induced
a significant reduction in the migration of the MSCs
towards the pan-chemoattractant FBS (Figure 4(g)). In
addition, we found a time-dependent significant reduc-
tion in exosome-induced TGFβ-1 secretion into the
growth media by the MSCs when the TGFβ-1 receptor
was blocked by a specific small-molecule inhibitor
(LY215799) (Figure 4(h)). Collectively, these results
strongly support the idea that TGFβ-1 on the exosome-
surface induces an enhanced migration phenotype and
TGFβ-1 response in MSCs.
Sustained TGFβ-1 signalling by endosomal
retention of exosomes and lysosome evasion
It iswell known thatTGFβ-1 rapidly activates cell signalling
by phosphorylation of SMADs, which is rapidly reduced
within 30 min [38,39]. Having observed similar signalling
activation and functional outcome for exosome-associated
TGFβ-1, we asked whether free TGFβ-1 induces similar
temporal signalling activation in MSCs in our system. To
test this, we used dose-matched concentrations of TGFβ-1
in its free form and in the exosome-associated form and
performed immunoblotting analysis for phosphorylated
SMAD2 (pSMAD2) in the recipient MSCs. First, we deter-
mined the amount of TGFβ-1 associated with our total
exosomes isolates after floating them on a density gradient.
We found approximately 18.5 pg of total TGFβ-1 in 30 µg
isolated exosomes, out of which approximately 40% was in
the active form of TGFβ-1. Hence, 0.3 pg of active TGFβ-1
was present per microgram of total exosomes, and there-
fore this was utilized for further experiments. Interestingly,
TGFβ-1 induced a different degree of activation at different
time points when associated with exosomes, producing
a lower degree of phosphorylation of SMAD2 at 30 min
(Supplementary Fig. 11) but with more sustained effects at
60min (Figure 5(a)). The difference in kinetics invited us to
investigate of the delayed TGFb-1 signalling via exosomes
provide any advantage over transit activation of free-
TGFβ-1. We further observed that exosomes stimulated
MSCmigration more efficiently than free TGFβ-1 at dose-
matched concentrations (≥30 pg/ml) (Figure 5(b)). These
data collectively suggest that the sustained low amplitude
signalling elicited by exosome-associated TGFβ-1 evokes
greater functional effects than the transient, high amplitude
signal evoked by free TGFβ-1.
To elucidate the difference in the signalling efficiency
of free versus exosome-associated active TGFβ-1, we
assessed the fate of exosome in intracellular compart-
ments, primarily comparing lysosomes and early endo-
somes. It has previously been reported that free TGFβ-1
is rapidly processed via lysosomes [40], and we hypothe-
sized that exosome-associated TGFβ-1 that is taken up
by recipient cells evades or is delayed in trafficking to
lysosomes, producing a prolonged intracellular TGFβ-
signal. Because it is not feasible to perform these experi-
ments at large scales using MSCs, we instead utilized
HEK293T cells. Briefly, a high-resolution fractionation
of cell organelles was performed to physically separate
lysosomes and early endosomes derived from HEK293T
cells that had been exposed to biotinylated-exosomes for
60 min (Figure 5(c) and (d), bottom two blots).
Furthermore, we detected endosome (EEA1) and lyso-
some (LAMP1) markers in the different density gradi-
ents (Figure 5(d), top four blots). The respective markers
were used to identify the endosome-enriched fraction
(EEF) and the lysosome-enriched fraction (LEF). We
observed that the EEF was highly enriched in biotiny-
lated proteins as compared with the LEF, suggesting that
the components of exosomes were at least partly taken
up by the cells and were retained in endosomes at this
time point (Figure 5(d), bottom two blots). The
observed prolonged exosome-associated TGFβ-1–
mediated activation of cells might therefore at least
partly be explained by lysosomal evasion of the
exosome.
To confirm the endosomal localization of the vesicle
components, two different approaches were taken. First,
EEF and LEF samples were incubated with organelle-
specific antibodies to pull down the endosomal and
lysosomal fractions (Supplementary Fig. 12, right
panel) again showing enrichment of biotinylated pro-
teins in the EEA1-specific pull-down (as a marker of
endosomes) compared to the LAMP1-specific pull-
down (as a marker of lysosomes) (Figure 5(e)). To
confirm this finding in human MSCs, we traced the
biotinylated exosomes by performing a similar orga-
nelle-specific pull-down of EEA1 and LAMP1 from
crude cytoplasmic preparation of MSCs. As for the
HEK293T cells, MSCs also showed a higher biotinyla-
tion signal in the endosomal vs. the lysosomal compart-
ments (Figure 5(f)). Secondly, we also looked for
endosomal traces in streptavidin-captured exosome bio-
tin to validate the finding. HEK293T cells were incu-
bated with biotinylated exosomes, and streptavidin-
coated beads were used to pull down the cellular com-
partments containing biotinylated proteins, where the
biotinylated exosomes proteins are present, as described
in supplementary Fig. 12 (Left panel). As expected, the
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a chemoattractant was performed by reverse migration assay. Data are presented as means ± SEM; n = 3; * p ≤ 0.05. (c) Outline
of the procedure to enrich endosomes and lysosomes from cells using differential density centrifugation. Briefly, a total of 100 mg of
cells was treated with biotinylated exosomes (100 μg/ml) for 60 min, after which the cells were lysed and centrifuged to remove
cells and debris. Supernatants were top loaded on an iodixanol density gradient followed by a second round of iodixanol density
gradient separation of the upper and lower fractions obtained from the first round of iodixanol density gradient. The final fractions
for the endosome-enriched fraction (EEF) and the lysosome-enriched fraction (LEF) were collected for subsequent experiments. (d)
Biotinylated EVs were incubated with HEK293T cells for 60 min, and organelles were isolated with an iodixanol gradient as
described in outline and probed to detect LAMP1, EEA1, and biotinylated-exosome distribution. (e) Organelles isolated with
iodixanol gradient from HEK293T treated with biotinylated exosomes followed by LAMP1 or EEA1 antibody-based capture and
probed for biotinylated exosome-proteins. (F) The presence of biotinylated exosomes proteins at 60 min was confirmed in the
organelle-enriched suspension of MSCs cells that were bound to LAMP1 or EEA1 antibody-coated beads.
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total amounts of proteins binding to the beads were
significantly higher in the EEF compared to the LEF
sample (Supplementary Fig. 12 (i)). Furthermore,
a higher percentage of the proteins was bound to the
streptavidin-coated beads in the EEF samples, while
a higher percentage of the proteins was unbound to
the beads in the LEF sample, indicating that more bio-
tinylated proteins, and thus exosomes, were present in
the endosome-enriched fraction. To further confirm
that the bead-bound material (biotinylated proteins)
originated from the organelles of interest, we identified
the early endosomal protein (EEA1) and lysosomal
(LAMP1) (Supplementary Fig. 12 (ii)) in the bead-
bound samples. In summary, the results of these collec-
tive experiments show that the exosomes remained in
the early endosomes, suggesting early avoidance of traf-
fic of the exosomes to the lysosomes and thus allowing
for prolonged TGFβ-1 signalling in the recipient cells.
Exosomes assist in the uptake of inactive TGFβ-1
into the endosomal compartment
Presence of exosomes in the endosomal compartment does
not guarantee the presence of TGFβ-1. We also know that
LAP actively binds to the active form of TGFβ-1 as demon-
strated in-vitro (Figure 6(a)). To determine the interaction
of LAP-associated TGFβ-1 with exosomes in-vitro we
incubated exosomes with recombinant human LAP-
TGFβ-1 tagged with histidine (LAP-TGFβ-1-His). This
tagged version (LAP-TGFβ-1-His) was used to distinguish
from endogenous LAP-TGFβ-1. This incubated mixture
(Exosomes + LAP-TGFβ-1-His) was loaded in the bottom
of the iodixanol density gradient. The samples were cen-
trifuged, and the floated exosomes were collected from
interphase of 10–24% iodixanol. Stable interaction of
LAP-TGFβ-1-His and exosomes was confirmed with
immunoblotting of the LAP-TGFβ-1-His along with exo-
some-associated protein (Flotillin-1) (Figure 6(b)).
This complex of exosomes and LAP-TGFβ-1-His
was traced in recipient MSCs by monitoring endoso-
mal compartments expressing red florescent protein
and anti-His-Alexa Fluor-488 co-localization events.
Exposure of MSCs for 60 min with exosomes and
LAP-TGFβ-1-His complex showed co-localization of
endosome and LAP-TGFβ-1-His (upper panel,
Figure 6(c)). This co-localization was undetectable at
30 min and with LAP-TGFβ-1-His alone (lower panel,
Figure 6(c)). The transition of the exosomes into the
endosomal compartment may be exposed to gradual
acidification, so we tested the impact of in vitro acid-
ification of exosomes in in-vitro reaction to determine
pH-dependent association of endogenous TGFβ-1
with exosomes. To our surprise, the release of
TGFβ-1 from exosomes was evident from pH 6 sug-
gesting the conversion of inactive LAP-TGFβ-1 to
active TGFβ-1 is very sensitive to small changes in
pH (Figure 6(d)). We then speculated as to whether
acidification of the cellular compartment is essential
for exosome-induced endosomal TGFβ signalling. We
determine SMAD2 activation with exosome in the
presence of an endosome-lysosome system acidifica-
tion inhibitor (Chloroquine) and found a partial
reduction in the activation of SMAD2 (Figure 6(e)).
Taken together, our data indicate that acidification of
the endosome-lysosome system could play an impor-
tant role in exosomal–TGFβ-1-induced endosomal-
signalling.
Discussion
This study describes in detail how TGFβ-1 is associated
to exosome membranes via heparinase sensitive surface
glycans, dissociates from the exosome under acidic
conditions, transforms from the latent to the active
form, and mediates signalling in endosomes. Further,
the exosomes-associated TGFβ-1 is more potent than
the free form of the molecule, and we show how exo-
some-associated TGFβ-1 induces enhanced MSC cell-
migration in vitro via SMAD2 signalling. We further
observed that exosome traffic primarily to the endoso-
mal compartment, and less to the lysosomes of the
MSCs, at a time when SMAD2 phosphorylation is
evident. Endosomal localization was evident for inac-
tive TGFβ-1, where pH-dependent release of active
TGFβ-1 from LAP could occur, which could explain
the higher potency and extended biological response to
exosome-associated TGFβ-1 compared to that of free
TGFβ-1. Taken together, these data indicate that exo-
some released by human mast cells can promote MSC
migration and phenotypic changes via endosomal
TGFβ-1 signalling.
We and others have previously suggested that bioac-
tive molecules on the EV surface can efficiently influ-
ence recipient cells, specifically by transfer of the stem
cell factor receptor c-Kit, which might enhance recipi-
ent lung cancer cell proliferation [3,41–43]. In the
current study, we have utilized an exosome-
membrane proteomics approach to identify the low-
abundance TGFβ-1 and its receptor (Supplementary
Table 1), and we performed experiments to identify
any biological functions this molecule might have.
Validation of the membrane proteomics data at single-
vesicle resolution confirmed the presence of TGFβ-1
on the exosomes surface (Figure 1(d)), which suggests
that this highly bioactive cytokine might mediate
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immediate biological responses when interacting with
a cell via TGFβ-1 receptor activation. Previous studies
have shown that free signalling factors like platelet-
derived growth factor, TGF-β, and fibroblast growth
factor can induce growth and differentiation of MSCs
and change the fate of MSC function, but our current
study suggests that the TGF-β-1 cytokine can be more
potent if associated with the exosome membrane. It is
possible that this enhanced potency depends on the
three-dimensional association of TGF-β-1 to the mem-
brane, facilitating its interaction with its receptor on
the recipient cell. Importantly, blocking exosomes-
associated TGFβ-1 with an antibody was sufficient to
significantly reduce TGFβ-signaling, further supporting
the importance of this bioactive molecule for the
observed biological effects in MSCs.
To validate that TGFβ-1 is specifically interacting
with exosomes and to rule out that the presence of
TGFβ-1 on exosomes might be mediated by centri-
fugation-induced aggregation, we extended the stu-
dies by using a pellet-free exosomes isolation method
(Supplementary Figure 3a). Indeed, non-pelleted exo-
somes captured on anti-TGFβ-1 beads were expres-
sing the tetraspanins CD81, CD63 and CD9, as well
as flotillin-1, strongly arguing that the presence of
TGFβ-1 on exosomes was not induced by a forceful
centrifugation step (Supplementary Figure 3E-F).
A detailed evaluation of the exosome-associated
TGF-β-1 suggested that approximately 40% was in
the active form and 60% was in the inactive form
(Figure 1(b)). This distribution of TGFβ-1 was dif-
ferent from what was observed in a previous study
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by Webber et al. (2010), where they suggested that
only ~2% of the TGFβ-1 from mesothelioma or
prostate cancer cell line-derived exosomes was in
the active form [13]. This further emphasizes that
mast cell-derived exosomes might have a greater pro-
portion of active TGFβ-1 compared to exosomes
derived from other cells, which potentially could
favour mast cell-derived exosomes in influencing
MSC function.
This study describes the mechanism by which mast
cell-derived exosomes can induce changes in MSCs to
become more migratory, as shown by a Matrigel-based
migration assay. The MSCs became dose-dependently
more migratory after pre-conditioning with exosomes
(Figure 4(f,g)). Previous approaches to treating different
diseases with MSCs include pre-treatments of MSCs
with cytokines such as TNF-α, IFN-γ, and IL-1β, and
these have resulted in some experimental success.
However, these approaches have suffered from problems
like induction of MSC differentiation, loss of immune-
suppressive function, and limited target usage in certain
treatments [44]. Unlike other methods, MSCs pre-
conditioned with mast cell-derived exosomes maintain
their multipotency (Supplementary Fig. 8) and immuno-
suppressive effects, which makes them interesting ther-
apeutic candidates in diverse diseases.
In all biological systems, free biomolecules such as
cytokines interact with surface receptors on cells,
resulting in downstream cellular signalling [45,46].
Interestingly, picogram concentrations of TGFβ-1 on
the surface of vesicles can contribute significantly to
downstream signalling, for example, phosphorylation
of SMAD2 (Figure 4(a)). It is thus likely that exosomes
present their surface molecules to recipient cells in
a unique context, which might explain the higher
potency of exosome-associated TGFβ-1 compared to
free molecules. Such mechanisms have indeed been
suggested for exosomes in other situations; for exam-
ple, they can enhance the oligomerization of prion
proteins by generating high local concentrations of
template and PrPc proteins and bringing them into
close proximity [45]. Additionally, we observed that
the inactive form of TGFβ-1 is associated with exo-
somes via surface glycans. It is possible that the glycan-
associated exosomes releases this inactive form of
TGFβ-1 as active TGFβ-1 by cleavage either by cell
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signalling in the endocytic compartment of MSCs induced by exosome-associated TGFβ-1.
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surface proteases or upon acidification within the
endosomal compartments. We observed that the asso-
ciation of inactive TGFβ-1 with exosomes was pH-
dependent, explaining the possible conversion of inac-
tive TGFβ-1 into its active form within endosomes
(Figure 6(d,e)). Thus, emerging evidence suggests that
significantly lower concentrations of bioactive mole-
cules can induce a stronger response when associated
with the exosomes, which ensures that the ligand is in
close proximity to its receptor.
When comparing the effects of exosome-associated
TGFβ-1 with free TGFβ-1, we could see both enhanced
and prolonged biological effects of the exosome-associated
cytokine, both in relation to migratory function as well as
pSMAD signalling in recipient MSCs at the 60-min time
point. It has previously been shown that TGFβ-1 alone
induces signalling by the activation of the TGFβ-1 recep-
tor, and this complex is rapidly internalized and is trans-
ferred to lysosomes for degradation [47,48]. Another study
has shown the transfer of TGFβ-1 receptor via EV assist in
SMAD2 signalling in receptor-deficient squamous cell
carcinoma tumour keratinocytes [49]. Unlike receptor
transfer, our current study purpose the transfer of bioactive
molecules to the inside of the recipient cells. The fate of
exosomes in recipient cells, which is known to involve
endosomal translocation [50,51], could at least partially
explain the longer signalling half-life of exosome-
associated TGFβ-1 over free TGFβ-1 observed in the cur-
rent experiments. To investigate this, we isolated early
endosomal and lysosomal compartments at a time point
where we know phosphorylation of SMAD2 was at its
highest, and we observed that biotinylated exosome-
proteins were preferentially located within the early endo-
somal compartments (EEA1-enriched), with a small
amount of biotinylated exosome-proteins in the lysosomal
compartment (Figure 5(c–f)) [52]. Therefore, the presence
of TGFβ-1 on the surface of exosomes seems to allow its
prolonged signalling, probably by avoiding degradation in
the lysosomes. Additionally, in vitro acidification of the
exosome showed that TGFβ-1 was dissociated from the
exosomes already at ~pH 6, and the exosomes then
induced less phosphorylation of SMAD2, further support-
ing that TGFβ-1 on the exosome-surface is crucial for the
phenotype change of the recipient cells (Figure 6(d,e)). In
this study, we suggest that inactive TGFβ-1 is attached to
exosomes via HSPGs, which bring TGFβ-1 to the endoso-
mal compartment. HSPG synthesis requires glucosamine-
N-deacetylase/N-sulfotransferase-1 to add glycan chains to
the glycoproteins. When this enzyme activity was diverted
by adding pNP-Xyl a comparative substrate glycan, we
observed a significant reduction of inactive-TGFβ-1 on
the exosomes, supporting the role of glycans in binding
the TGFβ-1 to the exosome-surface (Figure 2(d) and
Supplementary Figure 5). This was in accordance with
a previous study where endothelial cells from mouse lung
showed reduced secretion of TGFβ-1, IL-5, IL-2, and
Eotaxin in N-deacetylase/N-sulfotransferase-1–deficient
cells [53]. Furthermore, we depleted the glycan chains
(heparin and heparan sulfate) on exosomes in vitro with
the heparinase-II enzyme, which also significantly reduced
the presence of inactive TGFβ-1 on the exosomes (Figure 2
(b,c)). Removal of glycan chains from the exosomes did
not alter the uptake by MSCs in our experiments, which is
in line with an earlier study of exosome uptake into glio-
blastoma cells [54]. Interestingly, an observation made by
Webber, J. P et.al did not show any dependency of latent
TGFβ-1 binding on to the exosomes via Haparinase-II
sensitive elements. This could be due to the presence of
high abundant anionic heparin or chondroitin sulfate pro-
teoglycans from mast cells [55]. Interestingly, in humans,
a large proportion of secretory granules is produced by
mast cells and it is one of the richest sources of anionic
heparin or chondroitin sulfate proteoglycans [56].
Moreover, we have a large number of HSPG (e.g. synde-
can, glypican) in our exosomes preparation, as commonly
reported exosomes proteomics [29,30]. Binding of TGFβ-1
to the surface of exosome via HSPGs could indeed be
a novel strategy for long-term signalling by low-
abundance bioactive molecules, and putative expression
of other bioactive molecules on the surface of exosomes
could be an important pathway by which exosomes alter
recipient cell phenotypes.
Collectively, our findings suggest that exosomes
from mast cells can change the phenotype and function
of MSCs via TGFβ-1 bound to the surface of the exo-
somes via proteoglycans. In addition, the exosomes
taken up by the MSCs remain in the acidifying endo-
somal compartments at the time of cell signalling,
possibly via the pH-mediated release of latent TGFβ-1
to the active form. Further, the observed extended
phosphorylation of SMAD2 by TGFβ-1 on the exo-
somes suggests that significant changes in potency
and kinetics of responses can be observed when
a bioactive molecule is present on exosomes in its
free form. In conclusion, the surface of exosomes offers
a scaffold for bioactive proteins binding that required
endosomal environment for its activation/signalling.
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